

Lale Ozcan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3693489/publications.pdf>

Version: 2024-02-01

29
papers

3,891
citations

623734

14
h-index

642732

23
g-index

30
all docs

30
docs citations

30
times ranked

7232
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes. <i>Science</i> , 2006, 313, 1137-1140.	12.6	2,154
2	Role of Endoplasmic Reticulum Stress in Metabolic Disease and Other Disorders. <i>Annual Review of Medicine</i> , 2012, 63, 317-328.	12.2	374
3	Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. <i>Journal of Clinical Investigation</i> , 2009, 119, 2925-2941.	8.2	367
4	Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. <i>Nature</i> , 2018, 555, 673-677.	27.8	209
5	Calcium Signaling through CaMKII Regulates Hepatic Glucose Production in Fasting and Obesity. <i>Cell Metabolism</i> , 2012, 15, 739-751.	16.2	181
6	Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B ₄ synthesis by inhibiting a calcium-activated kinase pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14530-14535.	7.1	164
7	Activation of Calcium/Calmodulin-Dependent Protein Kinase II in Obesity Mediates Suppression of Hepatic Insulin Signaling. <i>Cell Metabolism</i> , 2013, 18, 803-815.	16.2	113
8	CAMKII β suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis. <i>Journal of Clinical Investigation</i> , 2017, 127, 4075-4089.	8.2	81
9	Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance. <i>Cell Reports</i> , 2016, 15, 2214-2225.	6.4	45
10	Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol. <i>Circulation Research</i> , 2019, 124, 38-51.	4.5	37
11	Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity. <i>Diabetes</i> , 2015, 64, 3396-3405.	0.6	31
12	Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. <i>Gastroenterology</i> , 2017, 153, 1568-1580.e10.	1.3	25
13	An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1. <i>Blood</i> , 2019, 133, 743-753.	1.4	23
14	Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity. <i>Journal of Clinical Investigation</i> , 2020, 130, 4348-4359.	8.2	20
15	Adipocyte CAMK2 deficiency improves obesity-associated glucose intolerance. <i>Molecular Metabolism</i> , 2021, 53, 101300.	6.5	15
16	Common Therapeutic Targets in Cardiometabolic Disease. <i>Science Translational Medicine</i> , 2014, 6, 239ps5.	12.4	13
17	Suppression of Adaptive Immune Cell Activation Does Not Alter Innate Immune Adipose Inflammation or Insulin Resistance in Obesity. <i>PLoS ONE</i> , 2015, 10, e0135842.	2.5	12
18	A Hepatocyte FOXN3- β Cell Glucagon Axis Regulates Fasting Glucose. <i>Cell Reports</i> , 2018, 24, 312-319.	6.4	10

#	ARTICLE	IF	CITATIONS
19	Endoplasmic Reticulum Stress in Cardiometabolic Disorders. <i>Current Atherosclerosis Reports</i> , 2012, 14, 469-475.	4.8	8
20	CaMKII in Cardiometabolic Disease. <i>Aging</i> , 2014, 6, 430-431.	3.1	3
21	A New Activator of Hepatocyte CaMKII in Fasting and Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1742-1744.	0.6	2
22	Targeting Soluble DPP-4 for Insulin Resistance: Origin Matters. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1460-e1462.	3.6	2
23	Allosteric MAPKAPK2 inhibitors improve plaque stability in advanced atherosclerosis. <i>PLoS ONE</i> , 2021, 16, e0246600.	2.5	1
24	A new player in hunger games. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	1
25	When fat is beneficial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	0
26	And the MVP award goes to: Major vault protein. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	0
27	More than a gut feeling. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	0
28	Biliopancreatic diversion is beyond just weight loss. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	0
29	Targeting NASH with OxPL neutralization. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	0